MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
Restricted accessResearch articleFirst published online September, 2023
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
FaginJA, WellsSAJr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med, 2016; 375(23):2307; doi: 10.1056/NEJMc1613118
2.
LandaI, IbrahimpasicT, BoucaiL, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest, 2016; 126(3):1052–1066; doi: 10.1172/JCI85271
3.
PozdeyevN, GayLM, SokolES, et al.Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res, 2018, 24(13):3059–3068; doi: 10.1158/1078-0432.CCR-18-0373
4.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014; 159(3):676–690; doi: 10.1016/j.cell.2014.09.050
5.
HoAL, GrewalRK, LeboeufR, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Eng J Med, 2013; 368(7):623–632; doi: 10.1056/NEJMoa1209288
6.
LeboulleuxS, Do CaoC, ZerdoudS, et al.A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E mutated differentiated thyroid cancer. Clin Cancer Res, 2023; doi: 10.1158/1078-0432.CCR-23-0046
7.
TherasseP, ArbuckSG, EisenhauerEA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000; 92(3):205–216; doi: 10.1093/jnci/92.3.205.
GildML, BullockM, TsangV, et al. Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics. Thyroid, 2023; 33(6):682–690; doi: 10.1089/thy.2022.0704
10.
CabanillasME, DaduR, IyerP, et al. Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid, 2020; 30(9):1288–1296; doi: 10.1089/thy.2019.0514
